Hydromorph Contin 30mg 12h-capsules Canada

Description

### HYDROMORPH CONTIN 30MG 12H-CAPSULES CANADA

### UNDERSTANDING HYDROMORPHONE HYDROCHLORIDE AND THE CONTROLLED-RELEASE FORMULATION

Hydromorphone hydrochloride is a potent semi-synthetic opioid agonist derived from morphine. It primarily binds to mu-opioid receptors in the central nervous system, altering the perception of and emotional response to pain. Hydromorph Contin is a **controlled-release capsule** designed to release hydromorphone slowly over a **12-hour period**. This makes it suitable for around-the-clock, continuous pain management in patients who require long-term opioid therapy.

Health Canada approves Hydromorph Contin exclusively for adults for the relief of severe chronic pain that can be adequately managed only with opioid therapy and that is not relieved by other treatment options . Due to the greater risks of overdose and death with controlled-release opioid formulations, it should only be used when alternative treatments are ineffective, not tolerated, or would be otherwise inadequate . A Canadian Specific Opioid targeted Risk Management Plan (CSO-tRMP) and a Drug Utilisation Study (DUS) have been submitted for this product .

### INDICATIONS FOR USE OF HYDROMORPH CONTIN 30MG IN CANADIAN PRACTICE

Hydromorph Contin 30mg 12h-capsules is indicated for the relief of severe chronic pain in adults requiring prolonged, continuous opioid therapy . In Canadian healthcare settings, it may be prescribed in contexts such as:

– Chronic cancer-related pain or palliative care under specialist supervision.
– Severe chronic non-cancer pain when non-opioid and non-pharmacologic options have been optimized and found insufficient.

**Limitations of Use :**
Because of the risks of addiction, abuse, and misuse with opioids, and because of the greater risks of overdose and death with controlled-release opioid formulations, Hydromorph Contin should only be used in patients for whom alternative treatment options (e.g., non-opioid analgesics) are ineffective, not tolerated, or would be otherwise inadequate to provide appropriate pain management. It is **not indicated** for:

– As-needed (PRN) analgesic use.
– Acute pain management, including use in outpatient or day surgeries.
– Peri-operative pain management.
– Mild, intermittent, or short-duration pain that can be managed with other pain medications.

### IMPORTANT SAFETY INFORMATION AND LIMITATIONS

**Opioid Tolerant Patients Only:** The 30 mg strength is **for use in opioid tolerant patients only** . This strength may cause fatal respiratory depression if administered to patients not previously exposed to daily hydromorphone equivalent dosages of 36 mg or more. Care should be taken in the prescribing of this capsule strength .

**Pediatrics:** No data are available to Health Canada. Therefore, Health Canada has not authorized an indication for pediatric use .

**Geriatrics:** In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, concomitant disease or other drug therapy .

### CONTRAINDICATIONS FOR HYDROMORPH CONTIN 30MG CANADA

Strict contraindications exist to protect patient safety :

– Hypersensitivity to hydromorphone, other opioids, or any ingredient in the formulation.
– Known or suspected mechanical gastrointestinal obstruction (e.g., bowel obstruction or strictures) or any diseases/conditions that affect bowel transit (e.g., ileus of any type).
– Suspected surgical abdomen (e.g., acute appendicitis or pancreatitis).
– Mild, intermittent, or short-duration pain that can be managed with other pain medications.
– The management of acute pain, including use in outpatient or day surgeries.
– The management of peri-operative pain.
– Acute or severe bronchial asthma, chronic obstructive airway, or status asthmaticus.
– Acute respiratory depression, elevated carbon dioxide (CO2) levels in the blood, and cor pulmonale.
– Acute alcoholism, delirium tremens, and convulsive disorders.
– Severe CNS depression, increased cerebrospinal or intracranial pressure, and head injury.
– Concurrent or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs).
– Women who are breast-feeding, pregnant, or during labour and delivery.

### SERIOUS WARNINGS AND PRECAUTIONS FOR HYDROMORPH CONTIN 30MG

Health Canada’s product monograph highlights a prominent Serious Warnings and Precautions Box :

– **Limitations of Use:** Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with controlled release opioid formulations, Hydromorph Contin should only be used in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate.
– **Addiction, Abuse, and Misuse:** Hydromorph Contin poses risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Each patient’s risk should be assessed prior to prescribing, and all patients should be monitored regularly. Hydromorph Contin should be stored securely to avoid theft or misuse.
– **Life-Threatening Respiratory Depression:** Serious, life-threatening, or fatal respiratory depression may occur with use. Risk is highest during initiation of therapy or following a dose increase. Infants exposed in-utero or through breast milk are at risk. Patients should be monitored for respiratory depression.
– **Accidental Exposure:** Accidental ingestion of even one dose, especially by children, can result in a fatal overdose.
– **Neonatal Opioid Withdrawal Syndrome:** Infants born to mothers physically dependent on opioids will also be physically dependent and may experience respiratory difficulties and withdrawal symptoms.
– **Interactions with Alcohol and CNS Depressants:** Combining with alcohol, benzodiazepines, or other sedatives greatly increases the risk of additive drowsiness and reduced breathing, which can be dangerous and life-threatening.
– **Administration Instructions:** **Do not cut, break, chew, dissolve, or crush the capsule or its contents**, as this can lead to rapid release and absorption of a potentially fatal dose of hydromorphone .

Canadian patients are encouraged to access take-home naloxone through provincial harm reduction programs.

### DOSAGE AND ADMINISTRATION OF HYDROMORPH CONTIN 30MG CANADA

**Important:** Do not take a single dose greater than 12 mg of Hydromorph Contin every 12 hours unless you are “opioid tolerant” – your doctor will determine this .

**How to Take Hydromorph Contin 30mg :**

– **Swallowed Whole:** Swallow the capsule whole with a full glass of water. Do not cut, break, chew, dissolve, or crush the capsule – this can be dangerous and life-threatening.
– **Sprinkled:** Open the capsule and sprinkle the entire contents onto a tablespoonful of warm (40°C) or cold (4°C) applesauce or room temperature (23°C) custard . Swallow the entire mixture immediately without chewing. Rinse your mouth and swallow the water. Do not keep any of the mixture for another dose. If you are unsure of the elapsed time or which food contains the mixture, discard all implicated food samples .

**Dosing Schedule:**

– Take every 12 hours .
– Take regularly and continuously to maintain its beneficial effects .

### COMMON AND SERIOUS SIDE EFFECTS OF HYDROMORPH CONTIN 30MG

**Very common side effects** include constipation, nausea, vomiting, drowsiness, dizziness, and sedation . To prevent constipation, drink plenty of water or juice and eat more dietary fibre . Other frequent effects may include dry mouth, headache, itching, sweating, and fatigue .

**Serious reactions** that require immediate medical attention or reporting to Health Canada’s Canada Vigilance Program include :

– **Respiratory depression:** slow, shallow, or weak breathing – a life-threatening emergency.
– **Serotonin syndrome:** a rare but potentially life-threatening condition with symptoms including fever, sweating, shivering, diarrhea, nausea, vomiting, muscle shakes or stiffness, fast heartbeat, confusion, agitation, restlessness, or hallucinations. Risk increases if taking certain antidepressants or migraine medications .
– **Adrenal insufficiency:** symptoms include nausea, vomiting, feeling tired, weak, or dizzy, and decreased appetite. Risk increases with opioid use longer than one month .
– **Opioid-induced hyperalgesia:** paradoxical increase in pain.
– **Allergic reactions or seizures.**
– **Withdrawal symptoms:** body aches, diarrhea, nausea, nervousness, restlessness, goose bumps, shaking, shivering, stomach cramps, fast heart rate, fever, sweating may occur if stopped suddenly .

### DRUG INTERACTIONS WITH HYDROMORPH CONTIN 30MG CANADA

Significant interactions can occur with :

– **Alcohol** – Do not drink alcohol while taking this medication. It can lead to unusually slow or weak breathing, serious side effects, or fatal overdose .
– **Other CNS depressants** – Benzodiazepines, sleeping pills, anxiety medications, antidepressants, sedatives, muscle relaxants, and antihistamines can cause additive drowsiness and reduced breathing which can be life-threatening .
– **Serotonergic medications** – Certain antidepressants (SSRIs, SNRIs, MAOIs, tricyclic antidepressants) and migraine treatments (triptans) increase risk of serotonin syndrome .
– **Anticholinergic drugs** – Increased risk of severe constipation or urinary retention.
– **Other medications** – St. John’s Wort, anticoagulants, some heart medications .

### LEGAL ACCESS AND PRESCRIBING IN CANADA

Hydromorph Contin is a controlled substance and can only be obtained with a valid prescription from a licensed Canadian prescriber. It is dispensed at licensed pharmacies across the country.

**Provincial Coverage:** The 30mg strength capsule is listed in provincial formularies such as the RAMQ list in Quebec . Provincial drug benefit plans may offer coverage under specific criteria. When travelling within Canada or internationally, patients must comply with federal regulations for controlled substances and carry proper documentation.

### PATIENT MEDICATION INFORMATION FOR HYDROMORPH CONTIN 30MG

Read the patient information leaflet supplied with your prescription. Key instructions include :

– Take exactly as directed by your healthcare professional – every 12 hours.
– Swallow capsules whole or sprinkle contents on applesauce/custard and swallow immediately without chewing.
– Do not share or sell the medication.
– Avoid driving or operating machinery until you understand how it affects you.
– Report any side effects promptly.

### STORAGE, HANDLING, AND DISPOSAL OF HYDROMORPH CONTIN 30MG CANADA

Store capsules at room temperature, protected from light, in the original child-resistant packaging . Keep locked away and out of sight/reach of children and pets. Dispose of unused or expired capsules through pharmacy take-back programs or authorized collection sites.

### FREQUENTLY ASKED QUESTIONS ABOUT HYDROMORPH CONTIN 30MG CANADA

**Can I open the capsule and sprinkle it on food?** Yes, you can open the capsule and sprinkle the contents on a tablespoon of applesauce or custard. Swallow immediately without chewing and rinse your mouth with water afterwards. Do not keep any mixture for another dose. If you forget which food you sprinkled it on or how long ago, discard the mixture .

**Can I drive while taking Hydromorph Contin 30mg?** It is not recommended until you know how the medication affects your alertness and coordination, as it can cause significant drowsiness and impair judgment .

**What should I do if I miss a dose?** Take it as soon as you remember, unless it is nearly time for the next scheduled dose. Do not double the dose. Consult your pharmacist or doctor for guidance.

**Is the 30 mg strength suitable for everyone?** No. The 30 mg strength is for use in opioid tolerant patients only. Taking this strength if you are not already on a daily dose of at least 36 mg hydromorphone equivalent can cause fatal respiratory depression .

### HISTORY AND MANUFACTURING OF HYDROMORPH CONTIN BY PURDUE PHARMA IN CANADA

Purdue Pharma has been a manufacturer of opioid analgesics in Canada for decades. Hydromorph Contin has been marketed in Canada since February 16, 1998 . The company’s production of controlled-release hydromorphone supports pain management options while adhering to Health Canada’s rigorous manufacturing and quality standards.

### THE CANADIAN REGULATORY FRAMEWORK FOR HYDROMORPH CONTIN 30MG

This product is regulated under the *Controlled Drugs and Substances Act* (CDSA) as a narcotic (CDSA I), the *Narcotic Control Regulations*, and the *Food and Drugs Act* . A Canadian Specific Opioid targeted Risk Management Plan (CSO-tRMP) has been submitted for this product, which includes Healthcare Professional Education materials and a Drug Utilisation Study (DUS) .

### SUPPORT RESOURCES FOR CANADIAN PATIENTS AND CAREGIVERS

– Provincial pain clinics and palliative care services.
– Addiction and mental health support programs.
– Public naloxone distribution initiatives.
– Health Canada and provincial ministry resources for safe medication use.

—

**DISCLAIMER:** This article is for informational and educational purposes only and is not medical advice. Hydromorphone is a potent Schedule I controlled narcotic available in Canada only by prescription. All use must be supervised by a licensed Canadian healthcare professional. Misuse or improper use can cause addiction, life-threatening respiratory depression, overdose, and death. In an emergency, call 911 or your provincial poison control centre immediately. Always verify the latest information on the Health Canada Drug Product Database and consult your healthcare team for personalized advice.

### CONCLUSION: RESPONSIBLE USE OF HYDROMORPH CONTIN 30MG IN CANADA

When prescribed and used appropriately under medical supervision in accordance with Health Canada standards and Canadian guidelines, Hydromorph Contin 30mg 12h-capsules can provide important long-term pain relief for patients requiring continuous opioid therapy. Patient safety, informed consent, adherence to directions, and collaboration with your healthcare team are essential. Prioritize non-opioid options whenever possible and utilize available support resources.

**DISCLAIMER:** This article is for informational and educational purposes only and does not constitute medical advice. Hydromorph Contin 30mg 12h-capsules is a prescription-only Schedule I controlled narcotic under the *Controlled Drugs and Substances Act* in Canada, manufactured by Purdue Pharma. It is authorized by Health Canada for the relief of severe chronic pain requiring the prolonged use of an oral opioid preparation. Always consult your licensed Canadian healthcare professional before starting, adjusting, or stopping this medication. Individual responses vary. Always verify the most current product information on the Health Canada Drug Product Database.

—

**Hydromorph Contin 30mg 12h-capsules Canada** is a controlled-release opioid analgesic produced by Purdue Pharma, a pharmaceutical company based in Toronto, Ontario . Marketed since February 16, 1998, this product meets stringent Health Canada standards for quality, safety, and efficacy . The 30 mg strength is a sustained-release capsule containing 30 mg of hydromorphone hydrochloride as the active ingredient (DIN: 02125390) . It is packaged in quantities of 50 capsules .